Supplementation of VigantOL® Oil versus Placebo as Add-on in Patients with Relapsing-Remitting MS receiving Rebif® treatment.

Registry ID

EUCTR2010-020328-23

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Merck Serono

Start date

2010-10-21

Completion date

2015-05-19

Last update

2026-08-16

Conditions

• RELAPSING REMITTING MULTIPLE SCLEROSIS
• Relapsing-Remitting Multiple Sclerosis

Summary

To assess the efficacy of Vigantol® oil versus placebo as add-on therapy in subjects with Relapsing-Remitting Multiple Sclerosis receiving treatment with Rebif®.

Locations

• , , Belgium
• , , Finland
• , , Italy
• , , Latvia
• , , Portugal
• , , Lithuania
• , , Estonia
• , , Denmark
• , , Germany
• , , Austria
• , , Netherlands

Related clinical trials

• A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

View on source registry